RegenoGel is a novel injectable viscoelastic gel that provides rapid, long-term pain relief and promotes regenerative healing of damaged cartilage due to degenerative joint disease or trauma. This effective, minimally invasive and safe solution promises new hope to patients suffering from pain and disability.
RegenoGel brings together two materials to create a novel “super” material. Using Procore’s proprietary platform technology, RegenoGel combines natural high molecular weight hyaluronic acid (HA) chemically linked to fibrinogen, a major plasma regulator of hemostasis and wound healing. This “perfect marriage” of non animal derived materials creates a highly safe and stable product. RegenoGel therefore shares the viscoelastic, protective and anti-inflammatory properties of HA with a fibrinogen-based matrix, to create a unique bio-compatible environment that stimulates the body’s own physiological regenerative processes.
RegenoGel acts in two phases. First, as a non-viscous liquid easily administered through a fine needle, it freely flows and spreads within the joint, filling fissures and cracks. Once settled into the damaged tissue, it transforms into a non-soluble stable gel. This transformation from liquid to solid dramatically enhances its supportive and soothing properties, providing lubrication and dissipating pressure to alleviate pain. Enriched with fibrinogen, this bio-environment is uniquely conducive to regenerative healing and optimal for natural tissue regeneration.
RegenoGel is available in two forms: RegenoGel-RG and RegenoGel-OSP. RegenoGel-OSP is an autologous version of RegenoGel with an added layer of personalized properties. RegenoGel-OSP (On Site Plasma) combines high molecular weight hyaluronic acid (HA) with the patient’s own plasma. The combined viscoelastic properties of hyaluronic acid with the growth promoting activity of soluble and platelet-associated factors alongside the regenerative, wound-healing properties of plasma fibrinogen. This unique combination offers a fully autologous and regenerative viscosupplementation material. RegenoGel-OSP is especially indicated for mild to severe osteoarthritis where there is enough residual joint cartilage capable of regeneration.
Both RegenoGel-RG and RegenoGel-OSP are approved for use by Israel’s Ministry of Health. Patients have been successfully treated since 2016 in several major medical centers with unprecedented results. Evidence based data from ongoing clinical trials and post-marketing evaluation that supports RegenoGel’s superior properties indicates significant pain relief, improved range of motion and enhanced quality of life.